2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Factor Xa

Factor Xa

Fxa

Factor Xa

Related Products

PDF 0.5 MB

Factor Xa, a trypsin-like serine protease, is situated at the critical juncture between the intrinsic and extrinsic pathways, catalyzing the conversion of prothrombin to thrombin, and hence plays a pivotal role in the final common pathway of the cascade and has become an important target in the discovery and development of new anticoagulants. Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.

Blood coagulation involves a complex cascade of enzymatic reactions, ultimately generating fibrin, the basis of all blood clots. This cascade is comprised of two arms, the intrinsic and extrinsic pathways which converge at factor Xa to form the common pathway. Factor Xa activates prothrombin to thrombin, which in turn catalyzes the conversion of fibrinogen to fibrin.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-134686
    Edoxaban impurity 4
    		Inhibitor 99.08%
    Edoxaban impurity 4 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention.
    Edoxaban impurity 4
  • HY-P6023
    D-Leu-Pro-Arg-Rh110-D-Pro
    		Chemical
    D-Leu-Pro-Arg-Rh110-D-Pro is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro can be used to detect FXIa activity.
    D-Leu-Pro-Arg-Rh110-D-Pro
  • HY-145354
    FXIa-IN-7
    		Inhibitor 98.59%
    FXIa-IN-7 is a selective and orally bioavailable factor XIa inhibitor with an IC50 value of 0.4 nM.
    FXIa-IN-7
  • HY-18660B
    Ciraparantag acetate
    		Inhibitor 98.0%
    Ciraparantag (PER977) acetate is a thrombin and factor Xa inhibitor. Ciraparantag acetate is a broad-spectrum reversal agent for anticoagulants, including low molecular weight heparins, unfractionated heparins, and some direct oral anticoagulants, but not VKAs.
    Ciraparantag acetate
  • HY-153480
    ARC19499
    		Inhibitor
    ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
    ARC19499
  • HY-122592
    Zifaxaban
    		Inhibitor 98.37%
    Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC50 of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research.
    Zifaxaban
  • HY-P6023B
    D-Leu-Pro-Arg-Rh110-D-Pro acetate
    		Modulator
    D-Leu-Pro-Arg-Rh110-D-Pro acetate is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro acetate consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro acetate can be used to detect FXIa activity.
    D-Leu-Pro-Arg-Rh110-D-Pro acetate
  • HY-P2933
    Activated protein C
    		Inhibitor
    Activated protein C is an anticoagulant targeting coagulation factors Va and VIIIa. Activated protein C demonstrates cytoprotective effects through binding to endothelial cell protein C receptor (EPCR) and protease-activated receptor-1 (PAR-1), regulating gene expression, anti-inflammation, anti-apoptosis, and stabilizing endothelial barriers. Activated protein C is promising for research of diseases such as severe sepsis and ischemic stroke.
    Activated protein C
  • HY-10268S
    Betrixaban-d6
    		Inhibitor 99.02%
    Betrixaban-d6 is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor.
    Betrixaban-d<sub>6</sub>
  • HY-P991117
    Amrecibart
    Amrecibart is an anti-coagulation factor 11 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).
    Amrecibart
  • HY-10268B
    Betrixaban hydrochloride
    		Inhibitor
    Betrixaban (PRT054021) hydrochloride is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban hydrochloride shows antithrombotic effect.
    Betrixaban hydrochloride
  • HY-128889
    FXIa-IN-1
    		Inhibitor
    FXIa-IN-1 (compound EP-7041) is a potent β-lactam covalent heparin-derived factor XIa (fXIa) inhibitor.
    FXIa-IN-1
  • HY-10264C
    Edoxaban hydrochloride
    		Inhibitor
    Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research.
    Edoxaban hydrochloride
  • HY-11091
    Razaxaban hydrochloride
    		Inhibitor
    Razaxaban hydrochloride (BMS 561389 hydrochloride) is a highly potent, selective and orally active factor Xa inhibitor with a Ki of 0.19 nM. Razaxaban hydrochloride exhibits excellent selectivity (>5000-fold) for factor Xa over other related serine proteases. Razaxaban hydrochloride is also a potent thrombin inhibitor with a Ki of 540 nM. Razaxaban hydrochloride has strongly antithrombotic activity.
    Razaxaban hydrochloride
  • HY-10769
    ZK-813039
    		Inhibitor
    ZK-813039 is a potent and orally active factor Xa inhibitor. ZK-813039 can prolong prothrombin time. ZK-813039 can be used for the research of cardiovascular disease.
    ZK-813039
  • HY-163347
    FXIIa-IN-3
    		Inhibitor
    FXIIa-IN-3 (Compound 8) is a potent and selective Factor XIIa (FXIIa) inhibitor, with an IC50 of 0.045 μM. FXIIa-IN-3 also exhibits a substantial margin of selectivity against related serine proteases, including FXIa, FXa, and FIXa. FXIIa-IN-3 can be used for the research of thromboembolic diseases.
    FXIIa-IN-3
  • HY-P991169
    Zemocimig
    		Inhibitor
    Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).
    Zemocimig
  • HY-129973
    4-Chlorophenylurea
    4-Chlorophenylurea is metabolite of diflubenzuron (HY-B1973). 4-Chlorophenylurea can be used to form factor Xa inhibitors.
    4-Chlorophenylurea
  • HY-10594
    Letaxaban
    		Inhibitor
    Letaxaban (TAK-442) is an orally active and selective direct FXa inhibitor. Letaxaban is a drug with dual anticoagulant and anti-inflammatory activity that works by directly inhibiting FXa and by intervening in the PAR1 signaling pathway. Letaxaban can be used in the study of thrombotic diseases, cardiovascular diseases and inflammation-related diseases.
    Letaxaban
  • HY-10777
    EMD 495235
    		Inhibitor
    EMD 495235 is a potent and orally active coagulation factor Xa inhibitor with an IC50 of 5.5 nM and a Ki of 6.8 nM. EMD 495235 shows anticoagulant activities.
    EMD 495235
Cat. No. Product Name / Synonyms Application Reactivity